Zetagen Therapeutics Awarded $2 Million USD Grant from the National Cancer Institute (NCI) for Phase 2 Study of ZetaMet™ (Zeta-BC-003) for Treatment of Metastatic Bone Cancers
December 13, 2021, (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced it has received a two year, $2 million USD grant from the National Cancer Institute of the National Institutes of Health (NIH).